Onkure Therapeutics, INC. (OKUR) — SC 13D/A Filings

All SC 13D/A filings from Onkure Therapeutics, INC.. Browse 3 SC 13D/A reports with AI-powered summaries and risk analysis.

SC 13D/A Filings (3)

Carlyle Group Files 13D/A Amendment for OnKure Therapeutics — Oct 10, 2024 Risk: medium
Carlyle Group Inc. has filed an amendment to its Schedule 13D, indicating a change in its beneficial ownership of OnKure Therapeutics, Inc. as of October 10, 20
NEA 15 Amends 13D Filing for OnKure Therapeutics — Oct 8, 2024 Risk: medium
New Enterprise Associates 15, L.P. (NEA 15) and its affiliated group, including Anthony A. Florence, Jr., Forest Baskett, Mohamad H. Makhzoumi, and Scott D. San
NEA 15 Amends Reneo Pharma Stake Filing — May 8, 2024 Risk: medium
On May 8, 2024, New Enterprise Associates 15, L.P. (NEA 15) filed an amendment to its Schedule 13D, reporting a change in beneficial ownership of Reneo Pharmace

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX